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Dopaminergic therapy has paradoxical effects on cognition in Parkinson’s disease
(PD) patients, with some functions worsened and others improved. The dopamine
overdose hypothesis is proposed as an explanation for these opposing effects of
medication taking into account the varying levels of dopamine within different brain
regions in PD. The detrimental effects of medication on cognition have been attributed
to exogenous dopamine overdose in brain regions with spared dopamine levels in PD.
It has been demonstrated that learning is most commonly worsened by dopaminergic
medication. The current study aimed to investigate whether the medication-related
learning impairment exhibited in PD patients is due to a main effect of medication
by evaluating the dopamine overdose hypothesis in healthy young adults. Using a
randomized, double-blind, placebo-controlled design, 40 healthy young undergraduate
students completed a stimulus-response learning task. Half of the participants were
treated with 0.5mg of pramipexole, a dopamine agonist, whereas the other half were
treated with a placebo. We found that stimulus-response learning was significantly
impaired in participants on pramipexole relative to placebo controls. These findings
are consistent with the dopamine overdose hypothesis and suggest that dopaminergic
medication impairs learning independent of PD pathology. Our results have important
clinical implications for conditions treated with pramipexole, particularly PD, restless leg
syndrome, some forms of dystonia, and potentially depression.
Keywords: stimulus-response learning, dopamine agonist, pramipexole, Parkinson’s disease, dopamine overdose
hypothesis
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative illness, characterized predominantly
by motor symptoms including tremor, rigidity, and bradykinesia (Jankovic, 2008). More recently,
deficits in cognition have also been described in PD patients (Dubois and Pillon, 1997).
Dopaminergic medications, such as levodopa (L-3,4-dihydroxyphenylalanine) or dopamine
receptor agonists, are prescribed with the main therapeutic goal of improving motor deficits in
PD patients (Hornykiewicz, 1974). However, the effects of dopaminergic therapy on cognition
are paradoxical, such that some aspects of cognition are improved whereas others are impaired
(Gotham et al., 1988; Cools et al., 2001; MacDonald and Monchi, 2011).
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Differences in endogenous dopamine levels within disparate
brain regions, related to PD pathophysiology, have been
proposed to account for these opposing effects of medication
on cognitive functions (Cools, 2006; MacDonald and Monchi,
2011). There is a progressive loss of dopaminergic neurons in
the substantia nigra (SN) resulting in dopamine depletion in
the dorsal striatum (DS), the brain region that it innervates
almost exclusively (Kish et al., 1988). This selective dopamine
deficiency in the SN is associated with the emergence of motor
impairments in PD but has also been related to deficits in
DS-mediated cognitive functions such as selective attention
and responding as well as task switching (Cools et al., 2001;
MacDonald et al., 2011; MacDonald and Monchi, 2011). In
contrast, dopaminergic neurons within the ventral tegmental
area (VTA) are relatively spared in PD patients (Haber and
Fudge, 1997). Subsequently, brain regions innervated by the
VTA, such as the ventral striatum, prefrontal and limbic cortices,
have relatively spared levels of endogenous dopamine, especially
at early disease stages (Haber and Fudge, 1997). Understanding
this pathophysiology, it has been contended that cognitive
operations mediated by VTA-innervated brain regions, such
as probabilistic reversal learning, learning associations between
stimuli, as well as stimuli and responses, remain unaffected at
baseline due to relatively replete dopamine levels (Cools et al.,
2001; Cools, 2006; MacDonald et al., 2011; MacDonald and
Monchi, 2011). The differential levels of endogenous dopamine
at baseline within the DS compared to the VTA-innervated brain
regions have provided a foundation to explain the paradoxical
effects of dopaminergic medication on cognition (Cools, 2006;
MacDonald and Monchi, 2011).
This dopamine overdose hypothesis has been proposed
as an explanation for the differential effects of dopaminergic
therapy on disparate cognitive functions (Gotham et al., 1988;
Cools, 2006; MacDonald and Monchi, 2011). Dopaminergic
medications are titrated to motor symptoms, which are
improved by restoring the maximally dopamine-depleted
DS (Hornykiewicz, 1974). These medication doses, however,
overdose VTA-innervated brain regions, disrupting their
functions (Gotham et al., 1988; Swainson et al., 2000; Cools
et al., 2001, 2007; MacDonald et al., 2013b; Hiebert et al., 2014b).
Accordingly, DS-mediated cognitive functions are improved
whereas dopaminergic therapy has detrimental effects on
functions mediated by relatively replete VTA-innervated brain
regions (Cools et al., 2001; MacDonald and Monchi, 2011).
In support of this, many studies have consistently shown that
dopaminergic medication improves PD patient performance on
various DS-mediated tasks (Cools et al., 2001, 2003; MacDonald
et al., 2011; Aarts et al., 2014) but impairs performance on tasks
associated with VTA-innervated brain regions (Swainson et al.,
2000; Cools et al., 2001; MacDonald et al., 2011).
Learning is the cognitive operation that appears to be
most commonly worsened by dopaminergic therapy. Exploring
performance on various learning tasks in PD patients on relative
to off medication has demonstrated therapy-related impairments
in stimulus-reward reversal (Swainson et al., 2000; MacDonald
et al., 2013b), sequence (Feigin et al., 2003), probabilistic
classification (Jahanshahi et al., 2010), abstract figure, and list
learning (MacDonald et al., 2013a). Further, stimulus-response
learning is impaired in PD patients on compared to off
dopaminergic therapy, but patients off medication exhibit
comparable learning to healthy age-matched controls (Vo
et al., 2014). In support of this, Hiebert et al. (2014a) used
functional magnetic resonance imaging (fMRI) to investigate the
brain regions involved in stimulus-response learning in healthy
young adults. They reported that learning stimulus-response
associations through feedback is mediated by the ventral striatum
(Hiebert et al., 2014a), a VTA-innervated brain region (Haber and
Fudge, 1997), explaining the effects of dopaminergic therapy on
stimulus-response learning in PD and supporting the dopamine
overdose hypothesis (Vo et al., 2014).
Overwhelmingly, investigations of the dopamine overdose
hypothesis are performed in PD patients. This strategy, however,
cannot resolve whether this is a main effect of dopaminergic
medications or whether dopamine overdose is the result of
a dopaminergic medication by PD pathology interaction. We
hypothesized that dopaminergic medication impairs learning
independent of PD pathology. A critical test of the dopamine
overdose hypothesis consequently involves testing the effect of
dopaminergic therapy on functions in healthy individuals (Vo
et al., 2016). Healthy young adults provide an ideal model
to investigate whether learning impairment is simply due to
dopamine overdose in VTA-innervated brain regions because
they have optimal endogenous dopamine levels presumably
(Haber and Fudge, 1997). The use of healthy young participants
eliminates a number of confounds that exist in PD such as
dopamine receptor sensitization secondary to chronic exposure
(Voon et al., 2009) as well as altered synaptic regulation
of dopamine in the form of decreased dopamine transporter
(DAT), which also occurs in PD (Harrington et al., 1996;
Kordower et al., 2013). In brief, if the mechanism for the
previously reported deficits in stimulus-response learning in
PD (Vo et al., 2014) is the straightforward result of dopamine
overdose to VTA-innervated brain regions (Hiebert et al.,
2014a), we expect dopaminergic therapy-related impairments in
healthy young adults that parallel effects in PD. In this respect,
studying medication effects on learning in healthy individuals
provides a critical test of the prevalent dopamine overdose
hypothesis.
Using a modified version of the stimulus-response learning
task, which previously demonstrated impairment in PD patients
on dopaminergic medication (Vo et al., 2014), we compared
the effects of pramipexole, a dopamine agonist, versus placebo
on stimulus-response learning in healthy young adults. We
predicted that participants treated with pramipexole would
exhibit impaired learning relative to placebo controls.
MATERIALS AND METHODS
Participants
Forty-five healthy young adults (29 females, 16 males) ranging
in age from 18 to 23 years (M = 20.69 years, SEM = 0.17)
participated in the present experiment. All individuals reported
no history of previous psychiatric or neurological disorders.
Individuals with current or past alcohol, prescription, or
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recreational drug abuse, or those who were taking cognitive-
enhancing medications (e.g., Methylphenidate, Donepezil,
Rivastigmine, Galantamine, or Memantine) were excluded from
participating. No participants presented with contraindications
for pramipexole (e.g., hypotension or treatment with
neuroleptics). No participant had prior experience taking
pramipexole. One individual met the exclusion criteria of
previous drug use and 4 participants withdrew from the study
due to adverse side effects (e.g., nausea, vomiting). Thus, 40
individuals (24 females, 16 males) were included in the final data
analysis.
This study was approved by the Health Sciences Research
Ethics Board of the University of Western Ontario. Prior
to testing, all participants provided informed written consent
to the approved protocol according to the Declaration of
Helsinki (World Medical Association, 2013). Participants were
compensated for their participation.
Affective and Cognitive Measures
Prior to the experimental task, participants completed a
series of written standardized cognitive and affective measures
to screen for pre-existing differences between our groups.
Anxiety, depression, and apathy were measured using the
Beck Anxiety Inventory (BAI, Beck and Steer, 1990), Beck
Depression Inventory-II (BDI-II, Beck et al., 1996), and
Starkstein Apathy Scale (Starkstein et al., 1992), respectively.
The Montreal Cognitive Assessment (MOCA, Nasreddine
et al., 2005), which includes measures of memory, executive
functioning, attention, visuospatial ability, abstraction, language,
concentration, calculation, and orientation, was used to screen
for cognitive impairment through both written and verbal tasks.
Verbal fluency was assessed by the total number of words
beginning with the letter F provided by the participant in 1
min as part of the MOCA (Nelson and Willison, 1991). Visuo-
constructional skills were compared using scores on the 3D
cube and clock drawing subsections of the MOCA (Nelson
and Willison, 1991). Finally, verbal IQ scores were computed
using the National Adult Reading Test (NART, Nelson and
Willison, 1991), which is a standardized measure of adult
intelligence.
Physiological and Mood Rating Measures
Measurements of heart rate, blood pressure, and alertness
(Bond and Lader, 1974) were collected three times during
the experiment: prior to capsule administration (i.e., pre-
administration), following a wait period but before beginning
the task (i.e., pre-test), and after completion of the task
(i.e., post-test). This allowed for assessment of the possible
physiological effects and changes to subjective mood attributable
to pramipexole.
Apparatus
The experiment was conducted on the Windows 7 operating
system. The computermonitor was placed∼50 cm away from the
participant for optimal viewing. A standard keyboard was used to
record key-press responses during the task.
Stimuli
The stimuli presented in the experiment were comprised of 12
abstract images. These images were computer-generated using
GroBoto (Braid Art Labs, Colorado Springs, USA) and are
displayed in Figure 1A.
Design and Procedure
All participants completed a testing session lasting ∼3 h.
To prevent interference with drug absorption, participants
refrained from caffeine, alcohol, and protein-rich foods on
the day of testing and from eating within 1 h before the start
of testing. Participants were randomly assigned to either the
drug or placebo condition, with half of participants receiving
0.5mg of pramipexole and the other half receiving an equal
volume of placebo. The dose used was selected based on
previous psychopharmacological studies of pramipexole in
healthy adults (Pizzagalli et al., 2008; Santesso et al., 2009).
Both drug and placebo were administered orally in identical
capsules to achieve double-blindness. Capsule preparation
and randomization were performed by a third party who
was not implicated in testing participants. Cognitive testing
commenced ∼2 h following ingestion of either capsule
to ensure that peak plasma pramipexole concentrations
were reached (Wright et al., 1997). Prior to beginning
the experimental task, participants completed a series
of practice trials to ensure that they understood the task
instructions.
During the experimental task, participants learned to associate
12 abstract images with one of three possible key-press responses.
Four images were assigned to each key (labeled “1,” “2,” or “3”).
On each trial, an image was presented and remained in the center
of the computer screen until the participant performed a key-
press response of either “1,” “2,” or “3” with their index, middle,
or ring finger of their dominant hand. Following each key-press
response, outcome feedback of either “Correct” or “Incorrect”
was provided. This feedback allowed for individuals to learn
associations among images and key-press responses through
trial and error. Participants were informed that the associations
between images and key-press responses did not change between
trials, thus allowing for learning to occur.
Each trial proceeded as follows: (a) a single image was
displayed until a key-press response was made; (b) a blank screen
was presented for 500ms; (c) either “Correct” or “Incorrect”
outcome feedback was displayed for 1000 ms; (d) a blank screen
appeared for 500ms to separate trials (see Figure 1B).
The experimental task was divided into five blocks of 24 trials
each. Each of the 12 abstract images was presented twice per block
in random order. At the end of each block, participants were
provided a percent accuracy score to summarize their learning
performance.
Data Analysis
For all demographic, cognitive, and affective control measures,
data were analyzed using independent t-tests contrasting scores
to compare pramipexole and placebo groups. For physiological
and alertness measures, we performed separate 2× 3 mixed
ANOVAs with Group (Pramipexole vs. Placebo) as the
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FIGURE 1 | (A) Computer-generated abstract images presented during the stimulus-response learning task (GroBoto, Braid Art Labs, Colorado Springs, USA). (B)
An example of a single stimulus-response learning trial.
between-subject factor and Time (Pre-administration vs. Pre-test
vs. Post-test) as the within-subject variable on heart rate, systolic
blood pressure, diastolic blood pressure, and alertness scores.
To assess stimulus-response learning, we performed separate 2
× 5 mixed ANOVAs with Group (Pramipexole vs. Placebo) as
the between-subject factor and Block (1 vs. 2 vs. 3 vs. 4 vs. 5)
as the within-subject variable on accuracy and response time
(RT) scores. Higher accuracy scores and faster RTs on each block
indicated more efficient learning.
RESULTS
Demographic, Affective, and Cognitive
Control Measures
Group demographics, including age and education level,
as well as scores on cognitive and affective measures, are
reported in Table 1. Independent t-tests revealed no significant
demographic, affective, or cognitive differences between
pramipexole and placebo groups (all p> 0.05; see Table 1).
Physiological Measures, Mood Ratings,
and Predictions
To assess the physiological and subjective mood effects of
pramipexole, we conducted separate 2 × 3 mixed ANOVAs on
heart rate, systolic blood pressure, diastolic blood pressure, and
alertness. Figure 2 displays the mean heart rate (see Figure 2A),
systolic blood pressure (see Figure 2B), diastolic blood pressure
(see Figure 2C), and alertness scores (Figure 2D) measured pre-
administration, pre-test, and post-test for the pramipexole and
placebo groups.
In regards to heart rate, we found a significant main effect
of Time [F(2, 74) = 32.40, MSE = 25.12, p < 0.001]. Post-hoc
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TABLE 1 | Demographic, cognitive, and affective measures for
pramipexole and placebo groups.
Measure Placebo (n = 20; Pramipexole (n = 20; p-value
12 females) 12 females)
Age 20.50 (0.29) 20.80 (0.21) 0.405
Education 15.40 (0.23) 15.55 (0.20) 0.628
NART 118.95 (1.45) 118.71 (0.99) 0.892
MOCA 27.80 (0.34) 27.80 (0.43) 1.000
F-words 14.00 (1.02) 12.75 (0.83) 0.347
Clock 2.95 (0.05) 2.90 (0.07) 0.560
Cube 0.85 (0.08) 0.90 (0.69) 0.643
BDI-II 9.60 (1.61) 8.05 (1.18) 0.441
BAI 8.60 (1.85) 7.45 (1.38) 0.622
Apathy 11.50 (1.07) 11.20 (0.77) 0.821
Mean values (±SEM) are reported. Education is measured in years. NART, National Adult
Reading Test indicates IQ score. The Montreal Cognitive Assessment (MOCA) is scored
out of 30, Clock is scored out of 3 and Cube is scored out of 1. BDI-II, Beck Depression
Inventory II is scored out of 63; BAI, Beck Anxiety Inventory is scored out of 63. Apathy is
scored out of 42.
pairwise comparisons revealed that heart rate pre-administration
was significantly higher than at both pre-test and post-test (both
p < 0.001; see Figure 2A). However, there was no significant
difference in heart rate between the pre-test and post-test period
(p = 0.281). There was no significant main effect of Group
on heart rate [F(1, 37) = 0.084, MSE = 269.69, p = 0.774].
We did find a significant Group × Time interaction effect
[F(2, 74) = 4.369, MSE = 25.12, p = 0.016]. Post-hoc pairwise
comparisons demonstrated that heart rate was significant lower
at pre-test (p = 0.035) and post-test (p = 0.010) compared to
pre-administration (see Figure 2A) for the pramipexole group,
but that pre-test and post-test measures did not significantly
differ (p = 1.000). Similarly, heart rate was significantly higher
at pre-test (p < 0.001) and post-test (p < 0.001) compared
to pre-administration for the placebo group, but pre-test and
post-test measures did not significantly differ (p = 0.275). These
findings indicate that the interaction effect was driven by Time
and not by Group.
Analysis of systolic blood pressure revealed a significant main
effect of Time [F(2, 74) = 3.541, MSE = 109.97, p = 0.034;
see Figure 2B]. Post-hoc tests demonstrated that systolic blood
pressure pre-administration was significantly higher than at
pre-test measure (p = 0.005) and there was no significant
difference between pre-administration and post-test (p = 0.090)
or pre-test and post-test measurements (p = 1.000). There was
neither a significant main effect of Group [F(1, 37) = 1.821,MSE
= 392.94, p= 0.185] nor a significant Group× Time interaction
effect [F(2, 74) = 0.192,MSE= 109.97, p= 0.825].
In regards to diastolic blood pressure, we found a significant
main effect of Time [F(2, 74) = 5.167, MSE = 59.78, p = 0.008;
see Figure 2C]. Post-hoc tests revealed that pre-administration
diastolic blood pressure was significantly higher than at both
pre-test (p = 0.035) and post-test (p = 0.034), and that pre-test
and post-test systolic blood pressure did not differ significantly
(p = 0.784). Lastly, we found neither a significant main effect
of Group [F(1,37) = 0.739, MSE = 135.98, p = 0.395] nor a
significant Group × Time interaction effect [F(2, 74) = 0.073,
MSE= 59.78, p= 0.930].
For alertness scores, we found a significant main effect of
Time [F(2, 76) = 13.650, MSE = 128.09, p < 0.001]. Pairwise
comparisons revealed that pre-administration alertness scores
were significantly higher compared to both pre-test (p = 0.001)
and post-test (p < 0.001), but there was no significant difference
in pre-test and post-test scores (p = 0.926). There was no
significant main effect of Group [F(1, 38) = 2.628,MSE= 496.90,
p = 0.113]. We found a significant Group × Time interaction
effect [F(2, 76) = 4.111, MSE = 128.09, p = 0.020], however,
reflecting greater change in alertness for pre- and post-test
relative to pre-administration scores for the pramipexole group
compared to the placebo group. Examining simple effects, these
differences relative to pre-administration reached significance for
the pramipexole group (p< 0.001 for both). Though the effect of
Time on alertness was large, η2 = 0.264, the Group x Time effect
was relatively small, η2 = 0.098. We attribute the main effect of
Time on alertness, collapsed across Group, to increased comfort
with the testing situation as well as some fatigue associated with
completing a number of demographic, clinical, and affective
questionnaires. The smaller effect of Group × Time, however,
reflected somewhat sedating property of pramipexole (Micallef-
Roll et al., 2001; Micallef et al., 2009). Despite these differences
across Time and related to pramipexole treatment, at no point
in the experiment did either group rate their level of alertness as
significantly somnolent (lowest mean alertness score was 45.31
on a 100-point scale). Potentially owing to the somewhat sedating
effect of pramipexole, despite double blinding, at the end of
the experiment, participants’ deduced their assigned group (i.e.,
pramipexole vs. placebo) with an accuracy of 72.5%.
Learning of Stimulus-Response
Associations
To compare learning performance between experimental groups
and across blocks, we performed a 2 × 5 mixed ANOVA
on accuracy scores. Figure 3A displays the mean accuracy
scores on each block (1-5) for the pramipexole and placebo
groups separately. We found a significant main effect of Block
[F(4, 152) = 91.648,MSE= 0.01, p< 0.001; η
2
= 0.707]. Post-hoc
pairwise comparisons revealed significant differences in accuracy
across all five blocks such that accuracy scores improved with
each subsequent block (all p < 0.001) as expected. There was
also a significant main effect of Group [F(1, 38) = 5.430, MSE =
0.07, p= 0.025; see Figure 3A], with significantly lower accuracy
scores in the pramipexole compared to the placebo group across
blocks. The effect size was moderate to large (η2 = 0.125).
Finally, there was no significant Group× Block interaction effect
[F(4, 152) = 0.238,MSE= 0.01, p= 0.916].
To further investigate the possibility that differences in
learning performance between pramipexole and placebo groups
were simply due to medication-induced decreases in alertness,
we conducted an additional 2 × 5 mixed ANOVA on key-
press RTs. Mean RTs for each block (1–5) are plotted for the
pramipexole and placebo groups separately in Figure 3B. There
was a significant main effect of Block [F(4, 152) = 24.593,
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FIGURE 2 | Mean (A) heart rate, (B) systolic blood pressure, (C) diastolic blood pressure, and (D) alertness scores for the pramipexole and placebo
groups at pre-administration, pre-test, and post-test. Error bars represent standard error of the mean. Means with different letters are significantly different; p <
0.05.
MSE = 76416.75, p < 0.001]. Post-hoc tests revealed that
RTs during Blocks 4 and 5 were significantly faster compared
to the first three blocks, and Block 3 was significantly faster
than the initial two blocks (both p < 0.05). There were
no statistically significant differences between Blocks 1 and 2
(p = 1.000) or between Blocks 4 and 5 (p = 0.196), however.
Most important though, we found no significant main effect of
Group [F(1, 38) = 0.181, MSE = 609848.42, p = 0.673], as
pramipexole and placebo control groups did not differ in their
RTs. There was also no significant Group × Block interaction
effect [F(4, 152) = 1.293,MSE= 76416.75, p= 0.275].
DISCUSSION
In the present study, we demonstrated that a single dose of
pramipexole, a dopamine agonist, impairs stimulus-response
learning in healthy young adults. This was indicated by lower
overall accuracy scores on a stimulus-response learning task in
the pramipexole group relative to a matched placebo control
group. We found that across blocks of this task, mean percent
accuracy scores increased, and mean key-press RTs decreased for
both groups, thus demonstrating that learning was achieved. The
differential learning performance between the pramipexole and
placebo groups was not due to pre-existing cognitive, affective,
or demographic differences as no significant differences in any
of these control measures were found. In addition, there were
no significant differences in physiological measures of heart rate,
systolic blood pressure or diastolic blood pressure between the
two groups at any time point. Thus, the learning impairment by
medication was not a consequence of the physiological effects of
the drug. Although heart rate and blood pressure significantly
decreased throughout the experiment, this occurred in both
groups and we attributed this finding to increasing comfort with
the testing situation and perhaps an element of general fatigue
and prolonged sitting over the experimental session. This was not
due to pramipexole, however, as there were no group differences
in these measures.
Alertness was reduced over time, collapsed across group,
from the pre-administration to the pre-test and post-test periods.
Although there was not a main effect of Group on alertness
scores, there was a Group × Time interaction, with lower
alertness scores for participants in the pramipexole group
relative to the placebo group at the pre-test and post-test time
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FIGURE 3 | Mean (A) percent accuracy scores and (B) key-press
response times from each block for the pramipexole and placebo
groups. Error bars represent standard error of the mean. Significant
differences between the two groups are marked with asterisks (p < 0.05).
points. Sedation is a recognized side effect of pramipexole and
others have demonstrated clinically significant sedation in young
healthy volunteers following administration of dopaminergic
medications (Micallef-Roll et al., 2001; Micallef et al., 2009).
This potentially accounts for the finding that participants were
above chance in accurately judging whether they had received
pramipexole or placebo. The effect size for the main effect
of Time was large, as suggested by η2 = 0.264, which we
attribute to increased comfort with the testing situation as
well as some fatigue associated with completing a number of
demographic, clinical, and affective questionnaires. The effect
size for the Group × Time interaction was quite small by
comparison (η2 = 0.098) and there was no main effect of
Group on alertness score. This effect on alertness was smaller
than the effect of pramipexole on learning score (η2 = 0.125),
suggesting that alertness alone may not account for differences in
learning between participants receiving pramipexole compared
to those receiving placebo. Further, despite these differences
across Time and to lesser extent related to pramipexole treatment,
at no point in the experiment did either group rate their level
of alertness as significantly somnolent (lowest mean alertness
score was 45.31 on a 100-point scale). Finally, we found no
significant differences in key-press RTs between the two groups
during the task. Though there are likely multiple influences
on RT, including possibly enhanced stimulus-reward value in
the pramipexole group (Hickey et al., 2010), if alertness was
significantly compromised due to pramipexole, equivalent RTs
across groups would be unexpected. Taken together, we interpret
that pramipexole-related learning impairment was likely not
entirely attributable to reduced alertness.
The current findings are consistent with the PD literature in
demonstrating detrimental effects of dopaminergic medication,
including pramipexole, on learning. Many studies have reported
various forms of learning impairments in PD patients related
to dopaminergic medication, including probabilistic associative
(Jahanshahi et al., 2010), list (MacDonald et al., 2013a), and
stimulus-reward reversal learning (Swainson et al., 2000; Cools
et al., 2001, 2007; MacDonald et al., 2013b). Vo et al. (2014)
reported that stimulus-response learning was impaired in PD
patients tested on their usual dopaminergic medications (i.e.,
levocarb and/or dopamine agonists as prescribed by their treating
neurologist), compared to when they were tested off medication
in a within-subject design. Our results are consistent with this
study in demonstrating that pramipexole, a dopamine agonist,
impaired learning in a slightly modified version of this same
stimulus-response learning paradigm.
As we have done here, investigations of the effects of
dopaminergic therapy on cognition have also recently been
conducted in healthy controls, to understand the main effect
that these medications have on cognition independent of
PD pathology (Vo et al., 2016). Our study contributes to
this small but growing literature that can determine whether
cognitive results are attributable in a straightforward manner to
dopaminergic therapy or whether they occur as an interaction
between medication and PD pathophysiology. The use of
healthy young adults, in particular, provides an ideal control
model for exploring the effects of dopaminergic medication on
cognition. This strategy is advantageous because it avoids the
significant variability in typical PD patient groups related to
wide age ranges, large differences in disease severity, medication
doses and types (Kalia and Lang, 2015). These studies also
can rule out the possibilities that these effects occur only (a)
secondary to dopamine receptor sensitization, through chronic
exposure to dopaminergic therapy, or (b) due to the fact
that PD-associated as well as aging-related reductions in DAT
levels, which clears and regulates dopamine at the synapse,
predisposing to dopamine overdose (Harrington et al., 1996;
Voon et al., 2009; Kordower et al., 2013; Kalia and Lang,
2015). Further, it is important to understand cognitive effects
of dopaminergic therapy independent of PD because these
medications are used in other conditions such as restless
leg syndrome (Liu et al., 2016), in some cases of dystonia
(Jankovic, 2013), and are being considered as therapy for
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depression (Cusin et al., 2013). Finally, if these cognitive effects
are main results of dopaminergic therapy, this should alert
clinicians to the possibility of cognitive improvements and
impairments related to dopaminergic medications at any stage
of PD.
Previous studies involving healthy individuals have evaluated
the effects of dopamine agonists on learning. These investigations
have revealed medication-related impairment in associative
(Breitenstein et al., 2006), probabilistic reversal (Mehta et al.,
2001), and reinforcement learning (Pizzagalli et al., 2008;
Santesso et al., 2009) in healthy adults. Results from the present
study are entirely in line with these findings. However, the current
results contribute the novel observation that pramipexole impairs
stimulus-response learning in healthy young adults, which has
not previously been investigated to our knowledge.
The dopamine overdose hypothesis explains the paradoxical
effects of dopaminergic therapy on cognition in PD patients as
owing to the varying endogenous levels of dopamine in the SN-
innervated DS compared to VTA-innervated brain regions. A
large literature links learning to VTA-innervated brain regions
such as the ventral striatum, hippocampus, and medio-frontal
and medio-temporal regions (Schendan et al., 2003; Rudy et al.,
2007; Denayer et al., 2008; Talpos et al., 2008; Cavanagh et al.,
2010; Guo et al., 2011; Hiebert et al., 2014a; Lungu et al.,
2014; Mattfeld and Stark, 2015) and not surprisingly in the
PD literature learning is the function vastly, most commonly
impaired by dopaminergic therapy. Indeed, with the stimulus-
response learning paradigm used here, (a) PD patients were
impaired by dopaminergic medication (Vo et al., 2014) and (b)
feedback-based learning was shown to be mediated by ventral
striatum using fMRI in healthy controls (Hiebert et al., 2014a),
strongly supporting this dopamine overdose hypothesis.
In the small literature investigating the effects of dopaminergic
therapy in healthy controls, learning is also by far the
function most frequently found to be impaired. In healthy
young participants, however, all brain regions are dopamine-
replete and therefore the straightforward dopamine overdose
hypothesis predicts that all cognitive functions that implicate
the neurotransmitter dopamine, not just those mediated by
VTA-innervated brain regions, should actually worsen with
dopaminergic therapy. There should be no specific predilection
or vulnerability for learning functions in healthy controls. For
example, cognitive functions such as task-set switching (Cools
et al., 2001), integration of various influences involved in
response selection (MacDonald et al., 2011), set-shifting and
conflict monitoring (Monchi et al., 2006; Ko et al., 2009),
as well as spatial attention (Christian et al., 2006), Stroop
interference (Vernaleken et al., 2007), and spatial working
memory (Sawamoto et al., 2008) depend upon dopamine and
should all be worsened in the on condition according to the
dopamine overdose account. These examples do not exist and
indeed there are a very small number of investigations in healthy
controls that in fact revealed improvements related to exogenous
dopamine administration in short-term spatial memory (Mehta
et al., 2001), working memory (Murphy et al., 2016), response
inhibition (Roesch-Ely et al., 2005), and novel word learning
(Knecht et al., 2004; Shellshear et al., 2015). At this point, it
is possible that the effects of dopaminergic therapy on these
other cognitive functions have not been investigated. It is equally
possible that these investigations have not revealed detrimental
effects in the form of between-group or between-condition
differences and therefore do not appear in the publication
record. Future studies should directly contrast, within the same
participants, the effects of dopaminergic therapy on cognitive
functions known to be mediated by brain regions innervated by
SN and those innervated by VTA, to investigate any particular
vulnerabilities. These studies should also include neuroimaging
measures to fully substantiate interpretations.
In summary, we have found that a single dose of the
dopamine agonist pramipexole impairs stimulus-response
learning in healthy young adults who have intact dopamine
levels and dopamine regulation functions. This confirms that
the detrimental cognitive effects of dopaminergic therapy are a
main effect of these drugs and do not arise only as an interaction
between these medications and PD pathology. The dopamine
overdose hypothesis is supported here. This has implications
for use of pramipexole in other conditions such as restless
leg, dystonia, or for potential future use of this medication in
depression. Further, this alerts clinicians to the potential of
detrimental effects of dopaminergic therapy, here pramipexole,
on learning in PD patients at all stages of disease, independent
of the nature or extent of their PD pathology. The serious
motor and cognitive symptoms in PD related to DS dopamine
deficiency obviously warrant dopaminergic therapy. However,
these results caution that the goal of therapy should be to strike
a better balance between these benefits and potential side effects
based on individual patient priorities and symptomatology.
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